Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study

Guillaume Fond, Laurent Boyer, Alexandru Gaman, Hakim Laouamri, Dodji Attiba, Jean Romain Richard, Marine Delavest, Josselin Houenou, Philippe Le Corvoisier, Dominique Charron, Rajagopal Krishnamoorthy, José Oliveira, Ryad Tamouza, Robert H Yolken, Faith Dickerson, Marion Leboyer, Nora Hamdani

Research output: Contribution to journalArticle

Abstract

The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known invitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T.gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). Methods: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their invitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. Results: BD patients with positive serum antibodies against T.gondii presented more lifetime depressive episodes (p=0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. Conclusions: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T.gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalJournal of Psychiatric Research
Volume63
DOIs
StatePublished - Apr 1 2015

Fingerprint

Toxoplasma
Bipolar Disorder
Schizophrenia
Cross-Sectional Studies
Psychotic Disorders
Therapeutics
Drug Prescriptions
Public Hospitals
Valproic Acid
Infection
Sex Characteristics
Pharmaceutical Preparations
Antipsychotic Agents
Multicenter Studies
Psychiatry
Inpatients
Outpatients
Randomized Controlled Trials
Demography
Antibodies

Keywords

  • Antipsychotic drugs
  • Bipolar disorder
  • Mood stabilizer
  • Schizophrenia
  • Toxoplasma gondii
  • Valproate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Arts and Humanities (miscellaneous)

Cite this

Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia : A cross-sectional study. / Fond, Guillaume; Boyer, Laurent; Gaman, Alexandru; Laouamri, Hakim; Attiba, Dodji; Richard, Jean Romain; Delavest, Marine; Houenou, Josselin; Le Corvoisier, Philippe; Charron, Dominique; Krishnamoorthy, Rajagopal; Oliveira, José; Tamouza, Ryad; Yolken, Robert H; Dickerson, Faith; Leboyer, Marion; Hamdani, Nora.

In: Journal of Psychiatric Research, Vol. 63, 01.04.2015, p. 58-64.

Research output: Contribution to journalArticle

Fond, G, Boyer, L, Gaman, A, Laouamri, H, Attiba, D, Richard, JR, Delavest, M, Houenou, J, Le Corvoisier, P, Charron, D, Krishnamoorthy, R, Oliveira, J, Tamouza, R, Yolken, RH, Dickerson, F, Leboyer, M & Hamdani, N 2015, 'Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study', Journal of Psychiatric Research, vol. 63, pp. 58-64. https://doi.org/10.1016/j.jpsychires.2015.02.011
Fond, Guillaume ; Boyer, Laurent ; Gaman, Alexandru ; Laouamri, Hakim ; Attiba, Dodji ; Richard, Jean Romain ; Delavest, Marine ; Houenou, Josselin ; Le Corvoisier, Philippe ; Charron, Dominique ; Krishnamoorthy, Rajagopal ; Oliveira, José ; Tamouza, Ryad ; Yolken, Robert H ; Dickerson, Faith ; Leboyer, Marion ; Hamdani, Nora. / Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia : A cross-sectional study. In: Journal of Psychiatric Research. 2015 ; Vol. 63. pp. 58-64.
@article{f0b085c19c8644629e83e53330d1730e,
title = "Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study",
abstract = "The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known invitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T.gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). Methods: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their invitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. Results: BD patients with positive serum antibodies against T.gondii presented more lifetime depressive episodes (p=0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. Conclusions: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T.gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.",
keywords = "Antipsychotic drugs, Bipolar disorder, Mood stabilizer, Schizophrenia, Toxoplasma gondii, Valproate",
author = "Guillaume Fond and Laurent Boyer and Alexandru Gaman and Hakim Laouamri and Dodji Attiba and Richard, {Jean Romain} and Marine Delavest and Josselin Houenou and {Le Corvoisier}, Philippe and Dominique Charron and Rajagopal Krishnamoorthy and Jos{\'e} Oliveira and Ryad Tamouza and Yolken, {Robert H} and Faith Dickerson and Marion Leboyer and Nora Hamdani",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.jpsychires.2015.02.011",
language = "English (US)",
volume = "63",
pages = "58--64",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia

T2 - A cross-sectional study

AU - Fond, Guillaume

AU - Boyer, Laurent

AU - Gaman, Alexandru

AU - Laouamri, Hakim

AU - Attiba, Dodji

AU - Richard, Jean Romain

AU - Delavest, Marine

AU - Houenou, Josselin

AU - Le Corvoisier, Philippe

AU - Charron, Dominique

AU - Krishnamoorthy, Rajagopal

AU - Oliveira, José

AU - Tamouza, Ryad

AU - Yolken, Robert H

AU - Dickerson, Faith

AU - Leboyer, Marion

AU - Hamdani, Nora

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known invitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T.gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). Methods: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their invitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. Results: BD patients with positive serum antibodies against T.gondii presented more lifetime depressive episodes (p=0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. Conclusions: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T.gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.

AB - The association between Toxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) and Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between one pathogen and psychiatric disorders. The aim of the present study was thus to retrospectively determine if the administration of an antipsychotic and/or a mood stabilizer having known invitro Anti-Toxoplasmic Activity (TATA+) was associated with a better clinical outcome in a population of 152 BD or 114 SZ patients and seropositive for T.gondii infection compared to patients receiving a treatment without anti-toxoplasmic activity (TATA-). Methods: This multicenter study was conducted in an academic public hospital during a 3-years period between 2009 and 2011. All consecutive inpatients and outpatients with SZ or BD diagnosis with a stable treatment for more than 4 weeks were recruited. socio-demographic and clinical characteristics measured with validated scales as well as a serological status for toxoplasmic infection were included. Treatments were classified according to their invitro antitoxoplasmic activity. A multivariate model was used to determine the clinical characteristics that were significantly different between patients receiving a treatment with no antitoxoplasmic activity compared to others. Results: BD patients with positive serum antibodies against T.gondii presented more lifetime depressive episodes (p=0.048) after adjustment for age, sex and sociodemographic characteristics when treated by drug having no anti-toxo activity, compared to patients having received drugs with anti-toxo activity. A significant difference was not found in BD toxonegative patients and in SZ toxopositive or toxonegative patients. Conclusions: It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to T.gondii, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity. Prospective randomized controlled trials are warranted to confirm this preliminary data.

KW - Antipsychotic drugs

KW - Bipolar disorder

KW - Mood stabilizer

KW - Schizophrenia

KW - Toxoplasma gondii

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=84926418176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926418176&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2015.02.011

DO - 10.1016/j.jpsychires.2015.02.011

M3 - Article

C2 - 25769398

AN - SCOPUS:84926418176

VL - 63

SP - 58

EP - 64

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -